Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Oct 10;30(1):956.
doi: 10.1186/s40001-025-02836-5.

Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study

Sema Hepşen  1 , Cem Haymana  2 , Burçak Cavnar Helvacı  3 , Halil Durantaş  3 , Bora Toros  2 , Ramazan Çakmak  4 , Mehmet Güven  5 , İbrahim Demirci  6 , Lezan Keskin  7 , Sinem Kıyıcı  8 , Zehra Yağmur Şahin Alak  8 , Mehmet Sargın  9 , Gonca Tamer  10 , Damla Balcı  10 , Berna İmge Aydoğan  6 , Arzu Or Koca  11 , Mustafa Aydemir  12 , İlhan Tarkun  13 , Pınar Köksal  14 , Ayten Oğuz  15 , Eda Demir Önal  16 , Süleyman Baldane  17 , Muhammed Kızılgül  3   18 , Erman Çakal  3 , Bekir Çakır  19 , Şefika Burçak Polat  19 , İlhan Yetkin  20 , Emre Bozkırlı  21 , Gülsüm Karaahmetli  19 , Sevgül Fakı  19 , Narimana Imanova Yaghji  22 , Ayşin Öge  23 , Burak Özbaş  11 , Şenay Topsakal  24 , Sevde Nur Fırat  25 , Hayri Bostan  26 , Barış Karagün  27 , Okan Sefa Bakıner  27 , Ayşe Kargılı Çarlıoğlu  28 , Bahri Evren  29 , Kader Uğur  30 , Faruk Kılınç  30 , Adnan Batman  31 , Selin Çakmak Demir  31 , Dilek Yazıcı  31 , Oğuzhan Deyneli  31 , Metin Arslan  20 , Omercan Topaloğlu  32 , Kübra Kocatepe  32 , Kemal Karagözoğlu  32 , Sakin Tekin  32 , Taner Bayraktaroğlu  32 , Sibel Ertek Yalçın  28 , Ayşe Kubat Üzüm  33 , Gökçem Yalın Kocamaz  34 , Mehtap Şahin  34 , Yusuf Aydın  35 , Mustafa Kutlu  28 , Tevfik Sabuncu  36 , Mustafa Cesur  6 , Volkan Demirhan Yumuk  37 , Fahri Bayram  34 , Alper Sönmez  6
Affiliations
Observational Study

Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study

Sema Hepşen et al. Eur J Med Res. .

Abstract

Background: The study aimed to evaluate real-world data on liraglutide by assessing its efficacy, associated side effects, adverse events, and impact on metabolic parameters within the context of a multicenter national study.

Methods: This retrospective observational study analyzed data from 1009 patients across 38 endocrinology units from Türkiye. Patients with a history of bariatric surgery, those who started orlistat concurrently with liraglutide, and one patient who developed pancreatitis on the 15th day of treatment were excluded from the analyses of weight and laboratory changes.

Results: At least one side effect was observed in 48% of the patients, with nausea and vomiting being the most common. The most frequent reason for discontinuing treatment was the cost of the medication (42.6%). The median duration of liraglutide use was 4 months (IQR; 3-6), and the median dose was 2.4 mg (IQR; 1.8-3). Among the entire cohort, 76.4% and 40.9% of patients achieved a 5% and 10% weight loss target, respectively. Significant reductions were observed in metabolic parameters during the treatment. The treatment duration was identified as an independent predictor for achieving 5% and 10% weight loss targets (B = 0.315, p < 0.001) and 10% weight loss (B = 0.216, p < 0.001).

Conclusions: Liraglutide effectively results in clinically significant weight loss, achieves expected weight loss targets, and improves metabolic parameters in real-world clinical practice. Therefore, liraglutide is still a reasonable GLP-1 analogue in the obesity treatment. However, it may be associated with various side effects, necessitating close monitoring by clinicians.

Keywords: GLP-1 analogue; Liraglutide; Obesity; Overweight.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval and consent to participate: This study protocol was reviewed and approved by “Scientific Research Assessment and Ethics Committee of Ankara Etlik City Hospital” on January 31, 2024, with the approval number AEŞH-BADEK-2024-101. Informed consent was obtained from participants. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The flow chart of patients in the liraglutide group and subgroups
Fig. 2
Fig. 2
Absolute weight changes and proportions achieving 5% and 10% weight loss during liraglutide treatment
See this image and copyright information in PMC

References

    1. World Health Organization (WHO). Obesity and overweight. Geneva: World Health Organization; 2024.
    1. Blundell JE, et al. Variations in the prevalence of obesity among european countries, and a consideration of possible causes. Obes Facts. 2017;10:25–37. - PMC - PubMed
    1. Satman I, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 2013;28:169–80. - PMC - PubMed
    1. Durrer Schutz D, et al. European practical and patient-centred guidelines for adult obesity management in primary care. Obes Facts. 2019;12:40–66. - PMC - PubMed
    1. Brown E, Cuthbertson DJ, Wilding JP. Newer GLP-1 receptor agonists and obesity-diabetes. Peptides. 2018;100:61–7. - PubMed

Publication types

LinkOut - more resources